These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 19287821)

  • 1. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 3. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 4. ACCORD and Risk-Factor Control in Type 2 Diabetes.
    Nilsson PM
    N Engl J Med; 2010 Apr; 362(17):1628-30. PubMed ID: 20228405
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
    Mehta A
    Postgrad Med; 2010 May; 122(3):61-70. PubMed ID: 20463415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951
    [No Abstract]   [Full Text] [Related]  

  • 10. [On behalf and the extent of evidence].
    Ruiz J
    Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic syndrome: is it a syndrome? Does it matter?
    Kahn R
    Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
    [No Abstract]   [Full Text] [Related]  

  • 12. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting of the minds. Should pre-hypertension in type 2 diabetes be treated?
    Bihl G; Amod A; Ellis G; Moore R; Raal FJ; Gernholtz T; Schamroth C; Horak A
    Cardiovasc J Afr; 2010; 21(3 Suppl):S9-S13. PubMed ID: 20532426
    [No Abstract]   [Full Text] [Related]  

  • 15. Introductory remarks.
    Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R
    Am J Ther; 2010; 17(3):236. PubMed ID: 20479578
    [No Abstract]   [Full Text] [Related]  

  • 16. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into understanding cardiometabolic risk. Introduction.
    Fonarow GC; Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
    [No Abstract]   [Full Text] [Related]  

  • 18. On the road to better dyslipidemia outcomes.
    Hughes S
    Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
    [No Abstract]   [Full Text] [Related]  

  • 19. FIELD study.
    Rees A
    Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
    [No Abstract]   [Full Text] [Related]  

  • 20. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.